Researches, authors, and/or edits complex clinical, scientific, and program-level regulatory documents, which may include Investigator's Brochures (IBs), Investigational New Drug (IND) application documents, and Marketing Authorization Application (MAA) documents. Serves as a primary author, providing strategic input and authoring regulatory documents supporting Phase 1 3 clinical drug development, including clinical study protocols, protocol amendments, and Clinical Study Reports (CSRs).